370 related articles for article (PubMed ID: 31087100)
21. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
22. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
Shapina MV; Nanaeva BA
Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
[TBL] [Abstract][Full Text] [Related]
24. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
25. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
26. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Dulai PS; Boland BS; Singh S; Chaudrey K; Koliani-Pace JL; Kochhar G; Parikh MP; Shmidt E; Hartke J; Chilukuri P; Meserve J; Whitehead D; Hirten R; Winters AC; Katta LG; Peerani F; Narula N; Sultan K; Swaminath A; Bohm M; Lukin D; Hudesman D; Chang JT; Rivera-Nieves J; Jairath V; Zou GY; Feagan BG; Shen B; Siegel CA; Loftus EV; Kane S; Sands BE; Colombel JF; Sandborn WJ; Lasch K; Cao C
Gastroenterology; 2018 Sep; 155(3):687-695.e10. PubMed ID: 29857091
[TBL] [Abstract][Full Text] [Related]
27. Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease.
Plevris N; Jenkinson PW; Chuah CS; Lyons M; Merchant LM; Pattenden RJ; Arnott ID; Jones GR; Lees CW
Frontline Gastroenterol; 2020 Mar; 11(2):117-123. PubMed ID: 32133110
[TBL] [Abstract][Full Text] [Related]
28. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
[TBL] [Abstract][Full Text] [Related]
29. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
[TBL] [Abstract][Full Text] [Related]
30. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
31. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.
Kopylov U; Avni-Biron I; Ron Y; Koslowsky B; Waterman M; Daher S; Ungar B; Schwartz D; Zittan E; Openhaim M; Yanai H; Maharshak N; Bar Gil Shitrit A; Naftali T; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Dig Liver Dis; 2019 Jan; 51(1):68-74. PubMed ID: 30172649
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
[TBL] [Abstract][Full Text] [Related]
34. Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
Sengupta NK; Azizov A; Halder S; Xenodemetropoulos T; Armstrong D; Tse F; Marshall JK; Narula N
Scand J Gastroenterol; 2020 Jul; 55(7):800-805. PubMed ID: 32574083
[No Abstract] [Full Text] [Related]
35. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
[TBL] [Abstract][Full Text] [Related]
36. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
38. Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
Bressler B; Yarur A; Silverberg MS; Bassel M; Bellaguarda E; Fourment C; Gatopoulou A; Karatzas P; Kopylov U; Michalopoulos G; Michopoulos S; Navaneethan U; Rubin DT; Siffledeen J; Singh A; Soufleris K; Stein D; Demuth D; Mantzaris GJ
J Crohns Colitis; 2021 Oct; 15(10):1694-1706. PubMed ID: 33786600
[TBL] [Abstract][Full Text] [Related]
39. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
40. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
